moxifloxacin has been researched along with linezolid in 125 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (linezolid) | Trials (linezolid) | Recent Studies (post-2010) (linezolid) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 3,916 | 222 | 2,188 |
| Protein | Taxonomy | moxifloxacin (IC50) | linezolid (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 8.19 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 2.1 | |
| Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial | Homo sapiens (human) | 8.19 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.80) | 18.2507 |
| 2000's | 46 (36.80) | 29.6817 |
| 2010's | 54 (43.20) | 24.3611 |
| 2020's | 24 (19.20) | 2.80 |
| Authors | Studies |
|---|---|
| Inagaki, H; Kawakami, K; Kawato, HC; Matsuhashi, N; Miyauchi, RN; Miyauchi, S; Ohki, H; Takahashi, H; Takemura, M | 1 |
| Inagaki, H; Takahashi, H; Takemura, M | 1 |
| Appelbaum, PC; Bhawsar, SB; Bozdogan, B; de Souza, NJ; Desai, VN; Deshpande, PK; Gupte, SV; Hooper, DC; Jacobs, MR; Jha, R; Khorakiwala, HF; Patel, MV; Shetty, N; Shukla, MC; Strahilevitz, J; Yeole, RD | 1 |
| Duewelhenke, N; Eysel, P; Krut, O | 1 |
| Frank, KL; Patel, R; Piper, KE; Reichert, EJ | 1 |
| Bouza, E; Cercenado, E; Cuevas, O; Marín, M; Martínez-Alarcón, J; Sánchez-Martínez, M | 1 |
| Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S | 1 |
| Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Hashimoto, A; Lucien, E; Marlor, CW; Nelson, DM; Ou, Y; Pais, GC; Podos, SD; Pucci, MJ; Song, Y; Thanassi, JA; Thoma, CL; Wang, Q; Wiles, JA | 1 |
| Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Mushtaq, G; Podos, SD; Pucci, MJ; Thanassi, JA; Thoma, CL; Vigliotti, GA | 1 |
| Chang, CL; Jeong, J; Jeong, SH; Jung, HJ; Kim, HR; Kim, S; Lee, EY; Lee, JN; Shin, JH | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Baudry, PJ; DeCorby, M; Hoban, DJ; Johnson, J; Karlowsky, JA; Lagacé-Wiens, P; Laing, N; McCracken, M; Mulvey, MR; Nichol, KA; Tailor, F; Vashisht, R; Walkty, A; Weshnoweski, B; Wierzbowski, A; Zhanel, GG | 1 |
| Daw-Garza, A; Lozano-Garza, HG; Ocampo-Candiani, J; Rocha, NC; Said-Fernández, S; Vera-Cabrera, L; Waksman de Torres, N; Welsh, O | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| del Pozo, JL; Mandrekar, JN; Patel, R; Rouse, MS; Sampedro, MF; Steckelberg, JM | 1 |
| Jacobus, NV; McDermott, LA; Snydman, DR | 1 |
| Bohnert, JA; Fähnrich, E; Kern, WV; Schuster, S; Wehmeier, C | 1 |
| Denis, O; Nguyen, HA; Struelens, MJ; Theunis, A; Tulkens, PM; Van Bambeke, F; Vergison, A | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Amaral, K; Dzink-Fox, J; Fischer, E; Goldovitz, J; Manni, K; Neckermann, G; Osborne, CS; Pecanka, R; Ryder, NS; Yu, D | 1 |
| Inagaki, H; Ito, M; Kawakami, K; Matsuhashi, N; Miyauchi, R; Ohki, H; Takahashi, H; Takemura, M | 1 |
| Bowker, KE; Caspers, P; Gaucher, B; MacGowan, AP | 1 |
| Cai, L; Gilbert, GL; Kong, F; Oftadeh, S; Xiao, M; Xu, X; Zhou, F | 1 |
| Chen, HC; King, CH; Lai, JF; Lauderdale, TL; Shiau, YR | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Angulo-Barturen, I; Beltrán, M; Cáceres, N; Cardona, PJ; García, JI; García-Bustos, JF; Rullas, J | 1 |
| Bajaksouzian, S; Biek, D; Critchley, IA; Good, CE; Jacobs, MR; Jones, RN; Sader, HS; Windau, AR | 1 |
| Bishai, WR; Grosset, JH; Nuermberger, EL; Zhang, T | 1 |
| Baek, SY; Chae, SE; Cho, YL; Jeong, JW; Jung, SJ; Kim, YZ; Kwak, JH; Lee, HH; Lee, HS; Park, TK; Woo, SH | 1 |
| Bradbury, BJ; Deshpande, M; Hashimoto, A; Kim, HY; Lucien, E; Nelson, DM; Pais, GC; Podos, SD; Pucci, MJ; Thanassi, JA; Wang, Q; Wiles, JA | 1 |
| Bradbury, BJ; Deshpande, M; Phadke, AS; Pucci, MJ; Thanassi, JA; Wiles, JA | 1 |
| Baulard, AR; Crauste, C; Déprez, B; Flipo, M; Villemagne, B; Willand, N | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
| Achar, V; Ambady, A; Awasthy, D; Bandodkar, B; Bellale, E; Chatterji, M; Guptha, S; Kaur, P; McLaughlin, R; Morayya, S; Naik, M; Narayan, A; Panda, M; Raichurkar, A; Ramachandran, V; Ravishankar, S; Sharma, S; V B, V; Vachaspati, P; Whiteaker, J | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bonnet, M; Cooper, CB; Denny, WA; Franzblau, SG; Lee, HH; Thompson, AM; Wan, B; Wong, GS | 1 |
| Eswaran, S; Narayanan, S; Shivarudraiah, P; Shruthi, TG; Subramanian, S | 1 |
| Xu, Z | 1 |
| Adeniyi, ET; Chen, S; Drießen, D; Ioerger, TR; Kalscheuer, R; Kruppa, M; Müller, TJJ; Rehberg, N; Sommer, GA; Tasch, BOA; Wang, L; Wolf, K; Zhu, K | 1 |
| Peters, G; von Eiff, C | 1 |
| Betriu, C; Boloix, A; Culebras, E; Gómez, M; Palau, ML; Picazo, JJ; Redondo, M; Sánchez, A | 1 |
| Chen, YC; Ho, SW; Hsueh, PR; Lu, JJ; Luh, KT; Pan, HJ; Teng, LJ; Wu, JJ | 1 |
| Gleckman, R | 1 |
| Longworth, DL | 1 |
| Cartwright, FD; Kenny, GE | 1 |
| Georgopoulos, A; Graninger, W; Grisold, A; Mueller-Uri, P; Presterl, E | 1 |
| Gottlieb, T; Leroi, MJ; Siarakas, S | 1 |
| Binstock, P; Keating, M; Kontoyiannis, DP; Nannini, EC; Samonis, G | 1 |
| Abb, J | 1 |
| Bercion, R; Carricajo, A; Celard, M; Chomarat, M; Croizé, J; Delubac, F; Fèvre, D; Frédénucci, I; Fuhrmann, C; Helfre, M; Lelièvre, H; Letouzey, MN; Mandjee, A; Marthelet, P; Meley, R; Perrier-Gros-Claude, JD; Ros, A; Roure, C; Smati, S; Thierry, J; Tous, J | 1 |
| López, M; Rodríguez, JC; Royo, G; Ruiz, M | 1 |
| López, M; Rodriguez Díaz, JC; Royo, G; Ruiz, M | 1 |
| García-Tapia, A; Rodríguez, JC; Royo, G; Ruiz, M | 1 |
| Borrás, R; de Julián-Ortiz, JV; Domínguez, V; Gálvez, J; García-García, A; Guna, R; Muñoz, C | 1 |
| Almela, M; Jurado, A; Marco, F; Mensa, J; Ortega, M; Soriano, A | 1 |
| Becker, K; Friedrich, AW; Peters, G; von Eiff, C | 1 |
| Heinze, A; Holzgrabe, U | 1 |
| Andries, K; Chauffour, A; Jarlier, V; Ji, B | 1 |
| Bolaños, M; Finegold, SM; Molitoris, D; Väisänen, ML | 1 |
| Chauffour, A; Jarlier, V; Ji, B; Lefrançois, S; Robert, J; Truffot, C | 1 |
| Flynn, HW; Harper, T; Miller, D | 1 |
| Arhin, FF; Belley, A; McKay, GA; Moeck, G; Neesham-Grenon, E; Parr, TR | 1 |
| Baietto, L; D'Avolio, A; De Rosa, FG; Di Perri, G; Garazzino, S; Patanella, S; Sciandra, M; Siccardi, M | 1 |
| Aggarwal, D; Janmeja, AK; Mohapatra, PR | 1 |
| Daley, CL | 1 |
| Buszewski, B; Fuchs, P; Kegler, R; Miekisch, W; Mundkowski, RG; Olszowy, P; Schubert, JK; Szultka, M | 1 |
| Davis, LT; Fiscella, RG; Glickman, RD; Kumar, N; Nijm, LM; Peterson, RJ; Tu, EY; Ulanski, LJ | 1 |
| Bertaina, C; Bignamini, E; Cordola, G; Esposito, I; Mignone, F; Milano, R; Pinon, M; Scolfaro, C; Tovo, PA | 1 |
| Appelbaum, PC; Glupczynski, Y; Kosowska-Shick, K; Lemaire, S; Tulkens, PM; Van Bambeke, F | 1 |
| Al-Nawas, B; d'Hoedt, B; Karbach, J; Mouratidou, A | 1 |
| Freeman, JT; Goh, TL; Jones, KL; Towns, CR; Wong, CS | 1 |
| Alvey, C; Choo, HW; Cuozzo, C; Damle, B; Kirby, D; Labadie, RR; Riley, S | 1 |
| Abbate, E; Ambroggi, M; Cufré, M; García, A; Gonzalez Montaner, P; Natiello, M; Ritacco, V; van Soolingen, D; Vescovo, M | 1 |
| Brown, DL; Drusano, GL; Heine, HS; Kulawy, RW; Louie, A; VanScoy, BD | 1 |
| Leggio, M; Podos, SD; Pucci, MJ; Thanassi, JA | 1 |
| Balcıoğlu, IC; Eraç, B; Gürpınar, T; Hoşgör-Limoncu, M; Limoncu, ME; Özbilgin, A | 1 |
| Erdogan-Yildirim, Z; Manafi, M; Sauermann, R; Schwameis, R; Strommer, S; Zeitlinger, MA | 1 |
| Helmy, SA | 1 |
| Jeong, BH; Koh, WJ; Kwon, YS | 1 |
| Jo, KW; Kim, DS; Kim, S; Kim, WS; Lee, JY; Lee, SD; Shim, TS | 1 |
| Hussain, T; Liaqat, F; Muhammad, J; Nazir, J; Rabbani, M; Shaheen, AY; Sheikh, AA | 1 |
| Freeman, J; Vernon, J; Vickers, R; Wilcox, MH | 1 |
| Blackmore, T; McNaughton, A; McNaughton, H | 1 |
| Deshpande, D; Gumbo, T; Nuermberger, E; Pasipanodya, JG; Srivastava, S; Swaminathan, S | 2 |
| Head, BM; Meyers, AF; Rubinstein, E | 1 |
| Freeman, J; Pilling, S; Vernon, J; Wilcox, MH | 1 |
| Olesen, JS; Wang, M; Wejse, C | 1 |
| Werth, BJ | 1 |
| Aarnoutse, RE; de Knegt, GJ; de Steenwinkel, JE; de Vogel, CP; van der Meijden, A | 1 |
| Mendel, C; Murray, S; Spigelman, M | 1 |
| Akkerman, OW; Alffenaar, JC; Bolhuis, MS; de Lange, WC; Kerstjens, HA; Oswald, LM; van der Werf, TS; Van Kampenhout, E | 1 |
| Chen, HC; Huang, CC; Huang, WC; Wu, MF | 1 |
| Dong, L; Fu, Y; Huang, H; Huo, F; Jing, W; Li, Y; Ma, Y; Pang, Y; Zhao, L; Zong, Z | 1 |
| Lu, J; Pang, Y; Song, Y; Zhang, Z | 1 |
| Akkerman, OW; Bathoorn, E; de Lange, WCM; Lokate, M; Louka, C; Pournaras, S; Ravensbergen, SJ; Stienstra, Y; van der Werf, TS | 1 |
| Peyrusson, F; Tulkens, PM; Van Bambeke, F | 1 |
| Ahmad, N; Ahuja, SD; Akkerman, OW; Alffenaar, JC; Anderson, LF; Baghaei, P; Bang, D; Barry, PM; Bastos, ML; Behera, D; Benedetti, A; Bisson, GP; Boeree, MJ; Bonnet, M; Brode, SK; Brust, JCM; Cai, Y; Caumes, E; Cegielski, JP; Centis, R; Chan, ED; Chan, PC; Chang, KC; Charles, M; Cirule, A; D'Ambrosio, L; Dalcolmo, MP; de Vries, G; Dheda, K; Esmail, A; Flood, J; Fox, GJ; Fréchet-Jachym, M; Fregona, G; Gayoso, R; Gegia, M; Gler, MT; Gu, S; Guglielmetti, L; Holtz, TH; Hughes, J; Isaakidis, P; Jarlsberg, L; Kempker, RR; Keshavjee, S; Khan, FA; Kipiani, M; Koenig, SP; Koh, WJ; Kritski, A; Kuksa, L; Kvasnovsky, CL; Kwak, N; Lan, Z; Lange, C; Laniado-Laborín, R; Lee, M; Leimane, V; Leung, CC; Leung, EC; Li, PZ; Lowenthal, P; Maciel, EL; Marks, SM; Mase, S; Mbuagbaw, L; Menzies, D; Migliori, GB; Milanov, V; Miller, AC; Mitnick, CD; Modongo, C; Mohr, E; Monedero, I; Nahid, P; Ndjeka, N; O'Donnell, MR; Padayatchi, N; Palmero, D; Pape, JW; Podewils, LJ; Reynolds, I; Riekstina, V; Robert, J; Rodriguez, M; Schnippel, K; Seaworth, B; Seung, KJ; Shim, TS; Singla, R; Smith, SE; Sotgiu, G; Sukhbaatar, G; Tabarsi, P; Tiberi, S; Trajman, A; Trieu, L; Udwadia, ZF; van der Werf, TS; Veziris, N; Viiklepp, P; Vilbrun, SC; Walsh, K; Westenhouse, J; Yew, WW; Yim, JJ; Zetola, NM; Zignol, M | 1 |
| Brown, DL; Derendorf, H; Drusano, GL; Heinrichs, MT; Louie, A; Maynard, MS; Peloquin, CA; Rand, KH; Sy, SKB | 1 |
| Das, A; File, TM; Gasink, LB; Gelone, SP; Goldberg, L; Paukner, S; Saviski, J; Seltzer, E; Sweeney, C; Talbot, GH; Wicha, WW | 1 |
| Khalid, UK; Kumar Verma, A; Mathuria, KK; Munjal, S; Myneedu, VP; Puri, MM; Sarin, R; Singla, N; Singla, R; Vohra, V | 1 |
| Del Parigi, A; Everitt, D; Li, H; Li, M; Mendel, C; Nedelman, JR; Salinger, DH | 1 |
| Akkerman, OW; Alffenaar, JC; Bolhuis, MS; Ghimire, S; Jongedijk, EM; Touw, DJ; van den Elsen, SHJ; van der Werf, TS; Wessels, M | 1 |
| Chhabria, M; Kudaravalli, P; Lesho, E; Pendela, VS | 1 |
| Caminero, JA; Caylà, JA; García-García, JM; García-Pérez, FJ; Palacios, JJ; Ruiz-Manzano, J | 1 |
| Fukui, M; Marumo, S; Shirata, M; Tamai, K; Yoshimoto, Y | 1 |
| Campbell, JR; Chan, ED; Gegia, M; Kwak, N; Lange, C; Lee, M; Menzies, D; Milanov, V; Winters, N; Yim, JJ | 1 |
| Jain, AK; Sharma, P | 1 |
| Draper, HR; Garcia-Prats, AJ; Hesseling, AC; Schaaf, HS; van der Laan, LE; Winckler, JL | 1 |
| Chen, Y; Fan, L; Gu, Y; Li, N; Liu, C; Liu, H; Liu, Y | 1 |
| Giacani, L; Haynes, AM; Mayans, MV; Mitjà, O; Nieto, C; Pérez-Mañá, C; Quintó, L; Romeis, E; Ubals, M | 1 |
| Ak, HK; Alffenaar, JW; Jongedijk, EM; Kim, HY; Marais, BJ; Pk, B; Ruiter, E; Sawleshwarkar, S; Touw, DJ | 1 |
| Basdeo, SA; Cahill, C; Cox, DJ; Gogan, KM; Gordon, SV; Keane, J; O'Connell, F; O'Sullivan, J; Phelan, JJ | 1 |
| de Jong, BC; Decroo, T; Gils, T; Lynen, L; Van Deun, A | 1 |
| Berry, C; Dodd, M; du Cros, P; Fielding, K; Kazounis, E; Liverko, I; McHugh, TD; Moodliar, R; Moore, DAJ; Motta, I; Ngubane, N; Nyang'wa, BT; Parpieva, N; Rassool, M; Ritmeijer, K; Solodovnikova, V; Spigelman, M; Tigay, Z | 1 |
| Alcaide, F; Andres, S; Aubry, A; Benmansour, H; Boarbi, S; Cambau, E; Chryssanthou, E; Cirillo, DM; Fernström, L; Fitzgibbon, MM; Fröberg, G; Giske, CG; Hyyryläinen, HL; Kahlmeter, G; Keller, PM; Machado, D; Maurer, FP; Mengshoel, AT; Mok, S; Nadarajan, D; Schön, T; Svensson, E; Turnidge, J; van Ingen, J; Viveiros, M; Werngren, J | 1 |
| Bock, M; Bruun, NE; Bundgaard, H; Christensen, JJ; Christiansen, U; Elming, H; Fosbøl, EL; Fuursted, K; Gill, S; Helweg-Larsen, J; Høfsten, D; Høiby, N; Ihlemann, N; Iversen, K; Kristensen, JH; Køber, L; Lemming, L; Lerche, CJ; Moser, C; Nielsen, HL; Pedersen, CT; Povlsen, JA; Pries-Heje, MM; Rosenvinge, FS; Schultz, M; Theut, AM; Tønder, N; van Hasselt, JGC; Wang, H | 1 |
| Arslan, N; Esen, N; Özkarataş, MH; Özkütük, AA | 1 |
| Aarnoutse, R; Boeree, M; Cho, YL; Dierig, A; Geiter, L; Gong, X; Heinrich, N; Hoelscher, M; Hoffmann, L; Jarchow-MacDonald, A; Liyoyo, A; Mbeya, B; McHugh, TD; Mhimbira, FA; Minja, LT; Mpagama, S; Ntinginya, N; Phillips, P; Rassool, M; Schultz, S; Sebe, M; Svensson, EM; Te Brake, L; Wallis, RS; Wildner, LM | 1 |
| Amouzou, Y; Cameron, DR; Carton, T; Chaves, RL; De Martino, A; Kühn, J; Le Fresne-Languille, S; Le Vacon, F; Leuillet, S; Nicolas-Metral, V; Nowakowska, J; Vuagniaux, G; Wittke, F | 1 |
| Alffenaar, JW; Aryal, S; Boorgula, GD; Dheda, K; Gumbo, T; Malinga, L; Raj, P; Shankar, P; Singh, S; Srivastava, S; Thomas, TA | 1 |
| Aalhoul, F; Cotton, F; Fage, D | 1 |
| Adeel, A; Ahmad, A; Ahmad, I; Aslam, H; Mushtaq, F; Raza, SM; Saleem, S | 1 |
| Faksri, K; Hinwan, Y; Kaewprasert, O; Sirichoat, A | 1 |
11 review(s) available for moxifloxacin and linezolid
| Article | Year |
|---|---|
Tuberculosis: the drug development pipeline at a glance.
Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Humans; Tuberculosis | 2012 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1,2,3-Triazole-containing hybrids with potential antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA).
Topics: Anti-Bacterial Agents; Drug Design; Methicillin-Resistant Staphylococcus aureus; Triazoles | 2020 |
What do the new antimicrobials offer? Weighing the advantages and disadvantages compared with traditional agents.
Topics: Acetamides; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Humans; Linezolid; Moxifloxacin; Oxazolidinones; Patient Selection; Quinolines; Treatment Outcome; United States; United States Food and Drug Administration; Virginiamycin | 2001 |
Microbial drug resistance and the roles of the new antibiotics.
Topics: Acetamides; Anti-Infective Agents; Atovaquone; Aza Compounds; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Enterococcus; Fluoroquinolones; Gatifloxacin; Humans; Linezolid; Methicillin Resistance; Moxifloxacin; Naphthoquinones; Oxazolidinones; Proguanil; Pseudomonas aeruginosa; Quinolines; Staphylococcus aureus; Streptococcus pneumoniae; Vancomycin; Vancomycin Resistance; Virginiamycin | 2001 |
Update in tuberculosis 2009.
Topics: Acetamides; Animals; Antitubercular Agents; Aza Compounds; Diarylquinolines; Fluoroquinolones; Humans; Linezolid; Mice; Moxifloxacin; Oxazolidinones; Quinolines; Rifampin; Tuberculosis; Tuberculosis Vaccines; Vitamin D; Vitamins | 2010 |
Tuberculosis: clinical trials and new drug regimens.
Topics: Acetamides; Adamantane; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Administration Schedule; Drug Design; Ethylenediamines; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Oxazolidinones; Spiro Compounds; Thiazines; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2014 |
Alternative pre-approved and novel therapies for the treatment of anthrax.
Topics: Alpha-Globulins; Anthrax; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Bacterial; Antitoxins; Bacillus anthracis; Bacterial Toxins; Daunorubicin; DNA Helicases; Doxorubicin; Drug Discovery; Fluoroquinolones; Humans; Interferon Inducers; Levofloxacin; Linezolid; Moxifloxacin; Ofloxacin; Polyketides; Serine Proteinase Inhibitors; Tilorone; Virulence | 2016 |
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Carbapenems; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Fluoroquinolones; Humans; Kanamycin; Levofloxacin; Linezolid; Moxifloxacin; Recurrence; Treatment Failure; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
Changes in treatment for multidrug-resistant tuberculosis according to national income.
Topics: Antitubercular Agents; Humans; Linezolid; Moxifloxacin; Rifampin; Tuberculosis, Multidrug-Resistant | 2020 |
Pretomanid for tuberculosis: a systematic review.
Topics: Antitubercular Agents; Humans; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2022 |
5 trial(s) available for moxifloxacin and linezolid
| Article | Year |
|---|---|
Lack of an effect of standard and supratherapeutic doses of linezolid on QTc interval prolongation.
Topics: Acetamides; Adult; Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones; Gram-Positive Bacterial Infections; Humans; Linezolid; Male; Middle Aged; Moxifloxacin; Oxazolidinones; Quinolines; Young Adult | 2011 |
Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.
Topics: Administration, Intravenous; Adult; Aged; Anti-Bacterial Agents; Diterpenes; Double-Blind Method; Female; Humans; Linezolid; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pleuromutilins; Pneumonia, Bacterial; Polycyclic Compounds; Randomized Controlled Trials as Topic; Thioglycolates | 2019 |
Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.
Topics: Antitubercular Agents; Computer Simulation; Diarylquinolines; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Heart Rate; Humans; Linezolid; Long QT Syndrome; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant | 2019 |
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
Topics: Administration, Oral; Adolescent; Adult; Antitubercular Agents; Drug Therapy, Combination; Humans; Linezolid; Moxifloxacin; Rifampin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2022 |
A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxaci
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Humans; Linezolid; Moxifloxacin; Oxazolidinones; Treatment Outcome; Tuberculosis, Pulmonary | 2023 |
109 other study(ies) available for moxifloxacin and linezolid
| Article | Year |
|---|---|
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
Topics: Anti-Bacterial Agents; Cyclopropanes; Drug Resistance, Bacterial; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Stereoisomerism; Structure-Activity Relationship | 2003 |
Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position.
Topics: Anti-Infective Agents; Cyclopropanes; DNA Topoisomerase IV; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2004 |
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Dogs; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Half-Life; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Mutation; Prodrugs; Quinolizines; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Vancomycin Resistance | 2005 |
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Antimycin A; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Chloramphenicol; Clindamycin; Dose-Response Relationship, Drug; Fluoroquinolones; Glycolysis; HeLa Cells; Humans; Lactic Acid; Linezolid; Macrolides; Mitochondria; Osteoblasts; Oxazolidinones; Rotenone; Tetracyclines; Time Factors | 2007 |
In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
Topics: Acetamides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Biofilms; DNA, Bacterial; Humans; Linezolid; Microbial Sensitivity Tests; Nafcillin; Oxazolidinones; Penicillin-Binding Proteins; Penicillins; Reverse Transcriptase Polymerase Chain Reaction; Staphylococcal Infections; Staphylococcus; Tetracycline | 2007 |
In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Minocycline; Nocardia; Nocardia Infections; Polymorphism, Restriction Fragment Length; Reverse Transcriptase Polymerase Chain Reaction; Tigecycline | 2007 |
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen | 2007 |
Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
Topics: Animals; Anti-Bacterial Agents; Cell Line, Tumor; Drug Resistance, Multiple, Bacterial; Female; Humans; Methicillin Resistance; Mice; Quinolones; Staphylococcus aureus; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors | 2007 |
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
Topics: Animals; Anti-Infective Agents; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Mice; Microbial Sensitivity Tests; Quinolones; Thiazoles | 2007 |
Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Genes, Bacterial; Hospitals; Humans; Korea; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Molecular Epidemiology; Mutation; Ofloxacin; Pneumococcal Infections; Polymerase Chain Reaction; Prevalence; Reserpine; Respiratory Tract Infections; Retrospective Studies; Streptococcus pneumoniae | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; Canada; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Population Surveillance | 2008 |
In vivo therapeutic effect of gatifloxacin on BALB/c mice infected with Nocardia brasiliensis.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Disease Models, Animal; Female; Fluoroquinolones; Gatifloxacin; Humans; Linezolid; Mice; Mice, Inbred BALB C; Nocardia; Nocardia Infections; Oxazolidinones; Treatment Outcome | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
Topics: Anti-Infective Agents; Biofilms; Bioreactors; Electricity; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Staphylococcus aureus; Staphylococcus epidermidis | 2009 |
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacteroides fragilis; Carbapenems; Doripenem; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests | 2008 |
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Proteins; Macrolides; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Mutagenesis, Site-Directed; Sequence Homology, Amino Acid | 2009 |
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
Topics: Anti-Bacterial Agents; Cell Line; Cystic Fibrosis; Dose-Response Relationship, Drug; Fusidic Acid; Gentamicins; Humans; Macrophages; Microbial Sensitivity Tests; Oxacillin; Phenotype; Protein Binding; Staphylococcus aureus; Thymidine | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
Topics: Acetamides; Amidohydrolases; Animals; Anti-Infective Agents; Female; Linezolid; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Structure; Oxazolidinones; Peptides; Pneumonia; Staphylococcus aureus; Streptococcus pneumoniae; Thigh | 2009 |
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
Topics: Anti-Bacterial Agents; Drug Design; Drug Resistance, Multiple; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship | 2009 |
In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
Topics: Folic Acid Antagonists; Gram-Positive Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Phthalazines; Staphylococcus aureus; Streptococcus | 2009 |
Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Child, Preschool; DNA Transposable Elements; Drug Resistance, Bacterial; Erythromycin; Genotype; Humans; Macrolides; Microbial Sensitivity Tests; New South Wales; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae | 2010 |
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Quinolones; Taiwan | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.
Topics: Acetamides; Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Drug Discovery; Ethambutol; Fluoroquinolones; Immunocompetence; Inhalation Exposure; Isoniazid; Linezolid; Mice; Mice, Inbred C57BL; Moxifloxacin; Oxazolidinones; Pyrazinamide; Quinolines; Reproducibility of Results; Rifampin; Tuberculosis, Pulmonary | 2010 |
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Communicable Diseases, Emerging; Drug Resistance, Multiple, Bacterial; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae; United States | 2010 |
Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.
Topics: Anti-Bacterial Agents; Erythromycin; Luminescent Proteins; Microbial Sensitivity Tests; Models, Genetic; Mycobacterium ulcerans; Reserpine; Tetracycline | 2010 |
In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Bacterial Infections; Gram-Positive Bacteria; Linezolid; Male; Mice; Mice, Inbred ICR; Oxazolidinones; Staphylococcus aureus; Vancomycin | 2010 |
Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).
Topics: Anti-Bacterial Agents; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Escherichia coli; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pyrrolidines; Quinolones; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors | 2011 |
Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
Topics: Anti-Bacterial Agents; Cell Line, Tumor; DNA Topoisomerase IV; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Methicillin-Resistant Staphylococcus aureus; Organoselenium Compounds; Piperidines; Quinolines; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Thiophenes; Topoisomerase II Inhibitors | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; High-Throughput Screening Assays; Humans; Mice; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Polymorphism, Single Nucleotide; Protein Kinases; Small Molecule Libraries; Structure-Activity Relationship; Thiazoles | 2014 |
Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid.
Topics: | 2017 |
Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Microsomes, Liver; Molecular Structure; Mycobacterium tuberculosis; Oxadiazoles; Quinolines; Structure-Activity Relationship | 2019 |
Nature-Inspired (di)Azine-Bridged Bisindole Alkaloids with Potent Antibacterial
Topics: Alkaloids; Animals; Anti-Bacterial Agents; Cell Line; Cell Survival; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Indoles; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Peritonitis; Pyruvate Kinase; Rabbits | 2020 |
Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Humans; Linezolid; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Oxazoles; Oxazolidinones; Quinolines; Staphylococcal Infections; Staphylococcus; Virginiamycin | 1999 |
Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Microbial; Drug Therapy, Combination; Erythromycin; Fluoroquinolones; Humans; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Oxazoles; Oxazolidinones; Quinolines; Streptococcus; Virginiamycin | 2000 |
Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Microbial; Drug Therapy, Combination; Fluoroquinolones; Gram-Positive Bacteria; Humans; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Oxazolidinones; Quinolines; Taiwan; Virginiamycin | 2000 |
Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities
Topics: 4-Quinolones; Acetamides; Aminoglycosides; Anti-Bacterial Agents; Aza Compounds; Erythromycin; Fluoroquinolones; Gatifloxacin; Humans; Hydrogen-Ion Concentration; Ketolides; Linezolid; Macrolides; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Mycoplasma hominis; Mycoplasma pneumoniae; Oxazolidinones; Quinolines; Tetracyclines; Tigecycline; Ureaplasma urealyticum; Virginiamycin | 2001 |
Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
Topics: Acetamides; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Base Sequence; Ciprofloxacin; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Methicillin Resistance; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Ofloxacin; Oxazolidinones; Polymerase Chain Reaction; Quinolines; Sensitivity and Specificity; Staphylococcus aureus; Teicoplanin; Vancomycin | 2001 |
E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid.
Topics: Acetamides; Anti-Infective Agents; Aza Compounds; Clostridioides difficile; Clostridium Infections; Cross Infection; Diarrhea; Fluoroquinolones; Fusidic Acid; Gatifloxacin; Humans; Linezolid; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Oxazolidinones; Quinolines; Sensitivity and Specificity; Vancomycin | 2002 |
Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Drug Therapy, Combination; Ethambutol; Fatal Outcome; Fluoroquinolones; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Linezolid; Male; Mefloquine; Middle Aged; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Oxazolidinones; Quinolines | 2002 |
In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Linezolid; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Mupirocin; Oxazolidinones; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Teicoplanin; Vancomycin; Virginiamycin | 2002 |
Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae.
Topics: Acetamides; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Ketolides; Lactams; Levofloxacin; Linezolid; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Oxazolidinones; Penicillin G; Pristinamycin; Quinolines; Streptococcus pneumoniae; Virginiamycin | 2002 |
In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
Topics: Acetamides; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Linezolid; Male; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Quinolines; Tuberculosis | 2002 |
In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Ofloxacin; Oxazolidinones; Quinolines; Spain | 2003 |
Action of fluoroquinolones and Linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Quinolines; Rifampin; Structure-Activity Relationship; Time Factors | 2004 |
In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium kansasii; Oxazolidinones; Quinolines | 2005 |
[In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis].
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Clindamycin; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Oxazolidinones; Quinolines; Rifampin; Staphylococcus aureus; Staphylococcus epidermidis | 2005 |
Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Cefuroxime; Cephalosporins; Fluoroquinolones; Genetic Variation; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Oxazolidinones; Phenotype; Quinolines; Staphylococcal Infections; Staphylococcus | 2005 |
Determination of the extent of protein binding of antibiotics by means of an automated continuous ultrafiltration method.
Topics: Acetamides; Anti-Bacterial Agents; Automation; Aza Compounds; Fluoroquinolones; Gatifloxacin; Linezolid; Moxifloxacin; Oxazolidinones; Protein Binding; Quinolines; Reproducibility of Results; Serum Albumin, Bovine; Technology, Pharmaceutical; Ultrafiltration | 2006 |
Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice.
Topics: Acetamides; Animals; Anti-Infective Agents; Aza Compounds; Diarylquinolines; Female; Fluoroquinolones; Leprosy; Linezolid; Mice; Moxifloxacin; Mycobacterium leprae; Nitroimidazoles; Oxazolidinones; Quinolines | 2006 |
In vitro activities of DX-619 and four comparator agents against 376 anaerobic bacterial isolates.
Topics: Acetamides; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Aza Compounds; Bacteria, Anaerobic; Fluoroquinolones; Humans; In Vitro Techniques; Inhibitory Concentration 50; Linezolid; Meropenem; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Oxazolidinones; Pyrrolidines; Quinolines; Quinolones; Thienamycins | 2006 |
In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
Topics: Acetamides; Amikacin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Foot; In Vitro Techniques; Linezolid; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium ulcerans; Nitroimidazoles; Oxazolidinones; Quinolines; Rifampin; Streptomycin; Survival Analysis; Time Factors | 2006 |
In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates.
Topics: Acetamides; Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Biological Availability; Coagulase; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Linezolid; Methicillin Resistance; Microbial Sensitivity Tests; Microbiological Techniques; Moxifloxacin; Oxazolidinones; Quinolines; Staphylococcal Infections; Staphylococcus; Vancomycin; Virginiamycin | 2007 |
Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Drug Synergism; Fluoroquinolones; Gentamicins; Glycopeptides; Humans; Linezolid; Lipoglycopeptides; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Oxazolidinones; Polysorbates; Quinolines; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Surface-Active Agents; Vancomycin Resistance | 2008 |
Simultaneous quantification of linezolid, rifampicin, levofloxacin, and moxifloxacin in human plasma using high-performance liquid chromatography with UV.
Topics: Acetamides; Anti-Bacterial Agents; Antibiotics, Antitubercular; Aza Compounds; Calibration; Chromatography, High Pressure Liquid; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Moxifloxacin; Ofloxacin; Oxazolidinones; Quality Control; Quinolines; Reference Standards; Reproducibility of Results; Rifampin; Solutions; Solvents; Spectrophotometry, Ultraviolet | 2009 |
Treatment of extensively drug-resistant tuberculosis.
Topics: Acetamides; Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Dose-Response Relationship, Drug; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Linezolid; Moxifloxacin; Oxazolidinones; Quinolines | 2009 |
Polypyrrole solid phase microextraction: A new approach to rapid sample preparation for the monitoring of antibiotic drugs.
Topics: Acetamides; Anti-Bacterial Agents; Anticoagulants; Aza Compounds; Chromatography, High Pressure Liquid; Daptomycin; Fluoroquinolones; Humans; Hydrogen-Ion Concentration; Linezolid; Moxifloxacin; Oxazolidinones; Polymers; Pyrroles; Quinolines; Salts; Solid Phase Microextraction | 2010 |
An adaptable HPLC method for the analysis of frequently used antibiotics in ocular samples.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Aza Compounds; Cefuroxime; Chromatography, High Pressure Liquid; Contact Lenses, Hydrophilic; Eye; Fluoroquinolones; Gatifloxacin; Linear Models; Linezolid; Moxifloxacin; Oxazolidinones; Quinolines; Rabbits; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Vitreous Body | 2010 |
Two pediatric cases of multidrug-resistant tuberculosis treated with linezolid and moxifloxacin.
Topics: Acetamides; Antitubercular Agents; Aza Compounds; Child, Preschool; Emigrants and Immigrants; Female; Fluoroquinolones; Follow-Up Studies; Humans; Infant; Italy; Linezolid; Male; Microbial Sensitivity Tests; Moldova; Moxifloxacin; Oxazolidinones; Quinolines; Romania; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2010 |
Activity of moxifloxacin against intracellular community-acquired methicillin-resistant Staphylococcus aureus: comparison with clindamycin, linezolid and co-trimoxazole and attempt at defining an intracellular susceptibility breakpoint.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Cell Line; Clindamycin; Community-Acquired Infections; Fluoroquinolones; Humans; Linezolid; Macrophages; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Oxazolidinones; Phagocytosis; Quinolines; Staphylococcal Infections; Trimethoprim, Sulfamethoxazole Drug Combination | 2011 |
Antibiotic susceptibility of cocultures in polymicrobial infections such as peri-implantitis or periodontitis: an in vitro model.
Topics: Acetamides; Actinobacillus Infections; Aggregatibacter actinomycetemcomitans; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Capnocytophaga; Coculture Techniques; Coinfection; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Linezolid; Metronidazole; Microbial Interactions; Minocycline; Moxifloxacin; Oxazolidinones; Penicillin G; Peptostreptococcus; Peri-Implantitis; Periodontitis; Quinolines; Sulbactam | 2011 |
Extensively drug-resistant tuberculosis: New Zealand's first case and the challenges of management in a low-prevalence country.
Topics: Acetamides; Adult; Aminosalicylic Acid; Antitubercular Agents; Aza Compounds; Cycloserine; Emigrants and Immigrants; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Imipenem; Linezolid; Lymph Nodes; Male; Moxifloxacin; Myanmar; New Zealand; Oxazolidinones; Quinolines; Radiography | 2011 |
Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine.
Topics: Acetamides; Adult; Antitubercular Agents; Argentina; Aza Compounds; Compassionate Use Trials; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Female; Fluoroquinolones; Humans; Linezolid; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Oxazolidinones; Quinolines; Retrospective Studies; Thioridazine; Treatment Outcome; Tuberculosis, Pulmonary | 2012 |
Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Bacillus anthracis; Ciprofloxacin; Doxycycline; Fluoroquinolones; Linezolid; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Models, Biological; Moxifloxacin; Oxazolidinones; Predictive Value of Tests; Quinolines; Spores, Bacterial; Thienamycins; Viral Load | 2012 |
Bactericidal activity of ACH-702 against nondividing and biofilm Staphylococci.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Biofilms; Fluoroquinolones; Linezolid; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Oxazolidinones; Quinolines; Quinolones; Rifampin; Staphylococcus; Thiazoles; Vancomycin | 2012 |
Investigation of in vitro antileishmanial activity of moxifloxacin, linezolid and caspofungin on Leishmania tropica promastigotes.
Topics: Acetamides; Aza Compounds; Caspofungin; Echinocandins; Fluoroquinolones; Leishmania tropica; Linezolid; Lipopeptides; Moxifloxacin; Oxazolidinones; Quinolines; Trypanocidal Agents | 2013 |
Effect of pulmonary surfactant on antimicrobial activity in vitro.
Topics: Acetamides; Animals; Anti-Infective Agents; Aza Compounds; Carbapenems; Colistin; Daptomycin; Doripenem; Fluoroquinolones; Linezolid; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Oxazolidinones; Pulmonary Surfactants; Quinolines; Staphylococcus aureus; Swine; Tigecycline | 2013 |
Simultaneous quantification of linezolid, tinidazole, norfloxacin, moxifloxacin, levofloxacin, and gatifloxacin in human plasma for therapeutic drug monitoring and pharmacokinetic studies in human volunteers.
Topics: Acetamides; Adult; Anti-Infective Agents; Aza Compounds; Chromatography, High Pressure Liquid; Drug Monitoring; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Limit of Detection; Linezolid; Male; Moxifloxacin; Norfloxacin; Oxazolidinones; Quinolines; Reproducibility of Results; Sensitivity and Specificity; Tinidazole; Young Adult | 2013 |
Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy.
Topics: Aged; Anti-Bacterial Agents; Clofazimine; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Linezolid; Lung Diseases; Male; Middle Aged; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Retreatment; Retrospective Studies; Rifabutin; Treatment Failure | 2014 |
Report-Isolation identification and control of vancomycin resistant Staphylococcus aureus.
Topics: Acetamides; Anti-Bacterial Agents; Cinnamomum zeylanicum; Clindamycin; Curcuma; Fluoroquinolones; Garlic; Humans; Linezolid; Mentha; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Nigella sativa; Oxazolidinones; Pakistan; Plant Extracts; Staphylococcal Infections; Staphylococcus aureus; Surgical Wound Infection; Syzygium; Vancomycin Resistance; Wound Infection | 2015 |
Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators.
Topics: Aminoglycosides; Anti-Bacterial Agents; Benzimidazoles; Ceftriaxone; Clostridioides difficile; Clostridium Infections; Drug Resistance, Multiple, Bacterial; Fidaxomicin; Fluoroquinolones; Humans; Linezolid; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Phenotype; Pyridines; Ribotyping; Vancomycin | 2016 |
Comprehensive cost of treating one patient with MDR/pre-XDR-TB in Wellington, New Zealand.
Topics: Adult; Amikacin; Aminosalicylic Acid; Anti-Bacterial Agents; Antitubercular Agents; Bronchoscopy; Clofazimine; Depression; Drug Costs; Emigrants and Immigrants; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Health Care Costs; Humans; India; Isoniazid; Linezolid; Male; Mediastinum; Microbial Sensitivity Tests; Moxifloxacin; New Zealand; Pyrazinamide; Radiography, Thoracic; Rifampin; Schizophrenia, Paranoid; Tuberculosis, Lymph Node; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pleural; Tuberculosis, Pulmonary | 2016 |
Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.
Topics: Age Factors; Antitubercular Agents; Bacterial Load; Cell Line; Child; Computer Simulation; Drug Antagonism; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Humans; Linezolid; Microbial Sensitivity Tests; Models, Theoretical; Moxifloxacin; Mycobacterium tuberculosis; Tuberculosis | 2016 |
A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.
Topics: Antitubercular Agents; Bacterial Load; beta-Lactams; Child; Computer Simulation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluoroquinolones; Humans; Linezolid; Microbial Sensitivity Tests; Models, Theoretical; Moxifloxacin; Mycobacterium tuberculosis; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2016 |
Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Drug Resistance, Multiple, Bacterial; Enterocolitis, Pseudomembranous; Fluoroquinolones; Humans; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Oxazolidinones; Polymerase Chain Reaction; Pyrrolidines; Quinolones; Ribotyping | 2017 |
Mycobacterium chelonae hand infection after steroid injection in a patient with rheumatoid arthritis receiving long-term linezolid therapy.
Topics: Adrenal Cortex Hormones; Aged; Amputation, Surgical; Anti-Bacterial Agents; Arthritis, Rheumatoid; Clarithromycin; Drug Therapy, Combination; Fluoroquinolones; Hand; Humans; Injections; Injections, Intra-Articular; Linezolid; Male; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Tenosynovitis | 2017 |
Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis.
Topics: Acetamides; Administration, Oral; Anti-Bacterial Agents; Drug Interactions; Fluoroquinolones; Humans; Kinetics; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Oxazolidinones; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Staphylococcus epidermidis; Tetrazoles; Trimethoprim, Sulfamethoxazole Drug Combination | 2017 |
Activity of moxifloxacin and linezolid against Mycobacterium tuberculosis in combination with potentiator drugs verapamil, timcodar, colistin and SQ109.
Topics: Antitubercular Agents; Colony Count, Microbial; Drug Interactions; Fluoroquinolones; Linezolid; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis | 2017 |
TB Alliance regimen development for multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Dose-Response Relationship, Drug; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Research Design; Rifampin; Tuberculosis, Multidrug-Resistant | 2016 |
Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis.
Topics: Adult; Antitubercular Agents; Female; Fluoroquinolones; Humans; Linezolid; Moxifloxacin; Mycobacterium tuberculosis; Pregnancy; Tuberculosis, Multidrug-Resistant | 2017 |
In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates.
Topics: Aminoglycosides; Anti-Bacterial Agents; Clarithromycin; Clofazimine; Cycloserine; Drug Synergism; Fluoroquinolones; Gentamicins; Humans; Linezolid; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium avium; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Sputum; Streptomycin | 2018 |
Topics: Antitubercular Agents; Beijing; China; Clofazimine; Diarylquinolines; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Gatifloxacin; Humans; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles | 2017 |
In vitro activity between linezolid and other antimicrobial agents against Mycobacterium abscessus complex.
Topics: Amikacin; Anti-Bacterial Agents; Cefoxitin; DNA-Directed RNA Polymerases; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Humans; Linezolid; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Tigecycline | 2018 |
Case Report: Carbapenemase-Producing Enterobacteriaceae in an Asylum Seeker with Multidrug-Resistant Tuberculosis.
Topics: Adult; Amikacin; Carbapenem-Resistant Enterobacteriaceae; Clofazimine; Drug Monitoring; Humans; Linezolid; Male; Moxifloxacin; Netherlands; Prevalence; Prothionamide; Refugees; Trimethoprim, Sulfamethoxazole Drug Combination; Tuberculosis, Multidrug-Resistant | 2018 |
Cellular Pharmacokinetics and Intracellular Activity of Gepotidacin against Staphylococcus aureus Isolates with Different Resistance Phenotypes in Models of Cultured Phagocytic Cells.
Topics: Acenaphthenes; Anti-Bacterial Agents; Azithromycin; Cell Line; Daptomycin; Heterocyclic Compounds, 3-Ring; Humans; Linezolid; Macrolides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Oxacillin; Phagocytes; Staphylococcus aureus; THP-1 Cells; Vancomycin | 2018 |
Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Humans; Linezolid; Microbial Viability; Models, Theoretical; Moxifloxacin; Mycobacterium tuberculosis; Treatment Outcome; Tuberculosis | 2019 |
Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
Topics: Adult; Antitubercular Agents; Cardiotoxicity; Clofazimine; Cycloserine; Diarylquinolines; Drug Therapy, Combination; Electrocardiography; Ethionamide; Female; Humans; India; Linezolid; Male; Moxifloxacin; National Health Programs; Sputum; Time Factors; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2019 |
Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin.
Topics: Adult; Antitubercular Agents; Drug Monitoring; Female; Humans; Linezolid; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Netherlands; Prospective Studies; Saliva; Tuberculosis, Multidrug-Resistant | 2020 |
Case Report: A Polymicrobial Vision-Threatening Eye Infection Associated with Polysubstance Abuse.
Topics: Administration, Ophthalmic; Adult; Anti-Inflammatory Agents; Antioxidants; Ascorbic Acid; Ceftazidime; Cocaine; Cocaine-Related Disorders; Coinfection; Dopamine Uptake Inhibitors; Doxycycline; Endophthalmitis; Female; Gram-Positive Bacterial Infections; Humans; Keratitis; Kingella; Linezolid; Moxifloxacin; Neisseriaceae Infections; Ophthalmic Solutions; Prednisone; Propionibacterium acnes; Streptococcal Infections; Streptococcus; Substance Abuse, Intravenous; Tobramycin; Vancomycin; Voriconazole | 2020 |
Update of SEPAR guideline «Diagnosis and Treatment of Drug-Resistant Tuberculosis».
Topics: Antitubercular Agents; Humans; Linezolid; Moxifloxacin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2020 |
In vitro efficacy of combinations of eight antimicrobial agents against Mycobacteroides abscessus complex.
Topics: Actinomycetales Infections; Amikacin; Anti-Bacterial Agents; beta-Lactams; Clarithromycin; Doxycycline; Humans; Imipenem; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacteriaceae; Sequence Analysis, DNA | 2020 |
Ethionamide induced blue vision (cyanopsia): Case report.
Topics: Aminosalicylic Acid; Antitubercular Agents; Color Vision Defects; Cycloserine; Ethionamide; Female; Humans; Kanamycin; Linezolid; Moxifloxacin; Tuberculosis, Multidrug-Resistant; Young Adult | 2020 |
Acceptability of levofloxacin, moxifloxacin and linezolid among children and adolescents treated for TB.
Topics: Adolescent; Anti-Bacterial Agents; Aza Compounds; Child; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Tuberculosis | 2020 |
Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: A single-center, retrospective, observational study.
Topics: Anti-Bacterial Agents; Antiviral Agents; China; COVID-19 Drug Treatment; Female; Glucocorticoids; Humans; Immunologic Factors; Indoles; Linezolid; Lopinavir; Male; Middle Aged; Moxifloxacin; Retrospective Studies; Ritonavir | 2021 |
Efficacy of linezolid on Treponema pallidum, the syphilis agent: A preclinical study.
Topics: Animals; Area Under Curve; Clofazimine; Disease Models, Animal; Drug Evaluation, Preclinical; Linezolid; Male; Microbial Sensitivity Tests; Moxifloxacin; Penicillin G Benzathine; Rabbits; ROC Curve; Syphilis; Treponema pallidum | 2021 |
Saliva-based linezolid monitoring on a mobile UV spectrophotometer.
Topics: Chromatography, High Pressure Liquid; Drug Monitoring; Linezolid; Moxifloxacin; Saliva | 2021 |
The Iron Chelator Desferrioxamine Increases the Efficacy of Bedaquiline in Primary Human Macrophages Infected with BCG.
Topics: Amikacin; Antitubercular Agents; Bacterial Load; Cell Survival; Clofazimine; Cycloserine; Deferoxamine; Diarylquinolines; Drug Resistance, Bacterial; Drug Synergism; Gene Expression; Humans; Interferon-gamma; Interleukin-1beta; Interleukin-6; Iron; Iron Chelating Agents; Linezolid; Macrophages; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium bovis; Primary Cell Culture; Pyrazinamide | 2021 |
Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution.
Topics: Amikacin; Anti-Bacterial Agents; Drug Resistance, Bacterial; Humans; Linezolid; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium abscessus; Mycobacterium avium; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nontuberculous Mycobacteria | 2023 |
Attainment of Target Antibiotic Levels by Oral Treatment of Left-Sided Infective Endocarditis: A POET Substudy.
Topics: Amoxicillin; Anti-Bacterial Agents; Dicloxacillin; Endocarditis; Endocarditis, Bacterial; Humans; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Rifampin | 2023 |
[Evaluation of Antimicrobial Susceptibilities of Rapidly Growing Mycobacteria].
Topics: Amikacin; Anti-Bacterial Agents; Cefoxitin; Ciprofloxacin; Clarithromycin; Doxycycline; Humans; Imipenem; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Tobramycin | 2023 |
Evaluation of the microbiota-sparing properties of the anti-staphylococcal antibiotic afabicin.
Topics: Animals; Anti-Bacterial Agents; Clindamycin; Humans; Linezolid; Mice; Microbiota; Moxifloxacin; Staphylococcus | 2023 |
Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen.
Topics: Antitubercular Agents; beta-Lactamase Inhibitors; Humans; Isoniazid; Linezolid; Meropenem; Moxifloxacin; Mycobacterium tuberculosis; Rifampin; Tuberculosis, Multidrug-Resistant | 2023 |
Protein binding investigation of first-line and second-line antituberculosis drugs.
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Levofloxacin; Linezolid; Moxifloxacin; Protein Binding; Pyrazinamide; Rifampin; Tuberculosis | 2023 |
Antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure.
Topics: Amikacin; Antitubercular Agents; Humans; Isoniazid; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant; Verapamil | 2023 |
Phenotypic drug-susceptibility profiles and genetic analysis based on whole-genome sequencing of Mycobacterium avium complex isolates in Thailand.
Topics: Amikacin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Humans; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Phylogeny; Thailand | 2023 |